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Progress towards the development of new thera- 
peutic agents is increasingly dependent upon rational 
experimental designs patterned after the mechanism 
of action of ‘lead’ discoveries [ I] . An elusive but much 
sought-after goal of medical research has been the 
development of specific, site-directed therapeutic 
agents. These agents would have little or no general 
toxicity towards the host but would seek-out a specific 
pathogen or cell type and then express a lethal 
toxicity. The rationale presented in this commentary 
is patterned after the mechanism of action of a 
specific, site-directed toxic agent. The behavior of 
certain derivatives of biogenic amines, of which 6- 
hydroxydopamine (6-HD) is the prototype, displays 
an impressive cellular specificity coupled with a lethal 
toxicity which is expressed only at specific cell types 
[2-41. This phenomenon occurs as a consequence 
of the substrate specificity of an active transport 
mechanism located in the plasma membrane of 
sympathetic neuronal terminals. This mechanism 
accepts the amine derivative in place of the naturally 
occurring amine and thus raises the intracellular 
concentration of the derivative to a critical concentra- 
tion which triggers a local toxicity. Thus, in this case 
there are two requirements for the expression of 
specific site-directed toxicity. One, the presence of 
an active transport mechanism localized in the plasma 
membrane of the cell and two, the molecular proper- 
ties of the derivative which is transported into the 
cell. The present commentary is restricted to a 
description of the mechanism by which amine 
derivatives, such as 6-HD, produce a localized neuro- 
degeneration of sympathetic nerve terminals. However, 
specific transport systems are known which can 
elevate the intracellular concentration of a variety 
of substances including amino acids, sugars, fats, 
and fatty acids. Such transport systems are present 
presumably to differing degrees in many, if not all, 
cell types including neoplastic cells. The present 
approach to the design of cell-specific toxic agents 
does not appear to be generally applicable to transport 
system common to many cell types. However, the 
variation in specificity and affinity for various 
compounds among different cell-types is sufficient 
to justify the proposed rationale. If such compounds 
also possessed the molecular properties common to 
the active form of 6-HD it is possible that they 
might be cell-specific toxic agents. An example of 
the application of this rationale has already led to 
the development of 5,6-dihydroxytryptamine [5] 
and 5,7-dihydroxytryptamine [6] - compounds 
which appear to induce degeneration in serotonergic 
neurons. Thus, the critical question pertaining to 
this rationale for the development of site-specific 
toxic agents concerns specific molecular mechanism 
by which 6-HD precipitates the cytotoxicity. 
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At present two mechanism for the specific cyto- 
toxic action of 6-HD in catecholamine-containing 
neurons have been proposed; one mechanism invokes 
the generation of cytotoxic moieties such as hydrogen 
peroxide, superoxide radical and hydroxide radical 
during the intraneuronal autoxidation of 6-HD [7] 
and the other invokes covalent reaction of the 
primary reaction product, the 1,4-paraquinone of 
6-HD (6-HDQ) with sulfhydryl groups on neuronal 
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proteins resulting in an extensive cross-linking and 
inactivation of protein constituents essential for the 
survival of the nerve terminal [8,9]. 
It is now clear that the cellular specificity of the 
cytotoxic action of 6-HD is a consequence of the 
specificity of the uptake mechanism for amines 
located in the plasma membrane of the neuronal 
terminal. Inhibition of this ‘membrane pump’ blocks 
the entrance of 6-HD into the axoplasm of the 
neuron and thus prevents the cytotoxic effect. 
However, for the cytotoxicity to be manifest a 
critical intraneuronal concentration of 6-HD must be 
achieved through the action of the transport system. 
While 6-HD has been shown to interact with specific 
constituents within the neuron such as the amine 
storage vesicle, monoamine oxidase, dopamine-B- 
oxidase and tyrosine hydroxylase, there is no evidence 
that these interactions are in any way specifically 
related to the cytotoxic effect [lo]. On the contrary, 
both of the proposed mechanisms uggest hat the 
rapid generation within the nerve terminal of highly 
reactive substances derived from the autoxidation 
of 6-HD elicits a nonspecific inactivation of cellular 
constituents. 
Studies of the interaction of 6-HD with various 
model proteins in vitro have clearly demonstrated 
that 6-HD reacts with nucleophilic groups on proteins 
to form a stable covalent bond. [ 11,9] . This reaction 
occurs readily at physiological pH and has an absolute 
requirement for molecular oxygen. The maximum 
extent of reaction of 6-HD with various proteins 
was achieved following unfolding of the tertiary 
structure of the protein in 4 M urea thus exposing 
sterically protected nucleophilic sites to attack 
presumably by 6-HDQ. Under these conditions a 
nearly stoichiometric relationship obtained between 
the binding of 6-HD and the number of sulfhydryl 
groups present on the protein either as free sulkydryl 
groups or in latent form as disulfide bonds. This 
relationship and the failure of 6-HD to react with 
the amino groups of polylysine indicate that sulfhydryl 
groups are the primary sites of reaction. 
The absolute requirement for oxygen, the ability 
of reducing agents such as ascorbic acid or sodium 
bisulfite to retard the reaction rate and the ability 
of sulfhydryl reagents like mercaptoethanol to 
interrupt the reaction of 6-HD with proteins strongly 
suggests that the reactive species is 6-HDQ, This 
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quinone is an electron-deficient species and is highly 
reactive with micleophiles [ 121. Electrochemical 
studies have demonstrated that the reaction rate 
of 6-HDQ with compounds bearing free sylfhydryl 
groups is substantially faster than the alternate 
possibilities such as: (1) reduction of 6-HDQ to 
6-HD, (2) internal nucleophylic attack resulting in 
the cyclization of 6-HDQ to 5,6-dihydroxyindole 
and (3) reaction with compounds bearing other 
nucleophilic groups like hydroxy or amino groups. 
The discovery that 6-HD at 10e4 M or greater not 
only bound to various proteins but resulted in the 
formation of insoluble protein complexes [8] was 
most pertinent to the proposed relationship between 
the model system and the cytotoxic effect in vivo. 
Examination of the reaction products of 6-HD with 
various proteins by gel filtration and SDS polyacryl- 
amide electrophoresis revealed a time-dependent 
formation of protein polymers of regularly increasing 
size. The products ranged from simple dimers, trimers, 
etc. to insoluble polymeric complexes with molecular 
weights in excess of 1 06. 
These results indicate that after the initial covalent 
reaction between an available sulfhydryl group on a 
protein and one of the two electron-negative centers 
on the aromatic ring of 6-HDQ, reoxidation can be 
followed by reaction of a second sulfhydryl group 
with the remaining electron-negative center, thus 
forming a dimer of two peptide chains. This cross- 
linking reaction involving additional molecules of 
6-HDQ proceeds until a complex protein lattice is 
generated. Proteins with only one or two sulfhydryl 
groups such as catechol-O-methyltransferase or 
human hemoglobin readily react with 6-HD but fail 
to undergo polymerization while horse hemoglobin 
with four sulfhydryl groups readily polymerized. The 
cross-linked complexes derived from bovine serum 
albumin, ovalbumin, and hemoglobin (horse), could 
not be dissociated by prolonged dialysis against 
various buffers, gel filtration, treatment with bisulfite 
or mercaptoethanol, treatment with 4 M urea and 
various detergents or by prolonged washing with 
either 0.4 N perchloric or trichloroacetic acid. 
Amino acid analysis, following hydrolysis of poly 
merized protein in 6 N HCl at 110°C for 24-72 h, 
revealed the presence of two new ninhydrin positive 
substances. Both of these substances contained 
radioactivity derived from the 3H-labeled 6-HD used 
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initially to induce the cross-linking reaction. The 
major product was a strongly basic substance and the 
minor product was similar in chromatographic 
behavior to serine. It was tentatively concluded that 
the major basic product was a cysteinyl derivative 
of 6-HD in which the ethyiamine side chain remained 
intact and the other minor product was a cysteinyl 
derivative in which the 6-HD portion had undergone 
intramolecular cyclization to an indole and thus lost 
its basic character. Thus, the irreversible nature of 
the interaction of the oxidation products of 6HD 
with sulfhydryl groups on proteins in vitro and the 
subsequent cross-linking of these proteins is compatible 
with the proposal that this mechanism may underlie 
the cytotoxic action of 6-HD in vivo. 
However, the direct extrapolation of the results 
of the interaction of 6-HD with proteins in vitro to 
the far more complex milieu of the sympathetic 
nerve terminal is unwarranted. Thus, a system more 
closely related to the conditions found in vivo was 
chosen to examine the cross-linking hypothesis for 
the mechanism of action of 6-HD. A clonal line of 
neuroblastoma cell, NI El 15, was chosen for this 
purpose because it possesses a number of similarities 
to the adrenergic neuron including the presence of 
large, dense core vesicles which bind catecholamines 
[ 131. Exposure of these cells to a non-lethal concen- 
tration of 3H-labeled 6HD resulted in a time-depen- 
dent, irreversible binding of 6-HD to various cell 
constituents and a dramatic change in the character 
of the intracellular proteins. Exa~nations of the 
treated cells revealed the presence of many high 
molecular weight proteins which were absent in 
preparations from untreated cells or in cells treated 
with dopa~ne. Virtually all of the 3H-labeled 6HD 
in the sample was irreversibly bound to these high 
molecular weight proteins. This evidence strongly 
suggests that 6-HD induced cross-linking of proteins 
in these cells and suggests an explanation of earlier 
reports of the toxic effects of 6-HD on a variety 
of cell cultures. 
Another in vitro system, the isolated mouse atria, 
has been used to study the relationship between 
proposed mechanism of action of 6-HD and the 
cytotoxic effect in vivo. One of the earljest manifesta- 
tions of the cytotoxic actions of &ND in vivo is a 
decrease in the neuronal uptake of norepinephrine. 
Pretreatment of mice with a cytotoxic dose (>l mg/ 
kg) of 6-HD results in a dose-dependent decrease 
in the uptake of norepinep~ine in mouse heart 
measured in vivo [ 141 or in atria1 preparations 
in vitro [ 151. This decrease can be clearly demon- 
strated as early as fifteen minutes after administration 
of 6-HD. Studies with 3H-Iabeled 6-HD demonstrated 
that as much as twenty percent of the amine taken 
up intraneuronally by the heart is covalently bound 
and that the time-course of the binding parallels 
the decrease in uptake of norepinephrine. In certain 
respects similar results have been obtained with 
isolated mouse atria exposed to 3H-labeled 6-HD in 
vitro. The uptake and irreversible binding of 3H- 
labeled 6-DA at a concentration of IO-’ M accumulated 
intraneuronally are nearly parallel for twenty minutes. 
The uptake of norepinephrine by atria under these 
conditions is unimpaired. Thus, it would appear that 
the covalent binding of 6-HD per se had failed to 
mimic the cytotoxic effect found in vivo. However, 
continued incubation of atria1 preparations, which 
showed no further covalent binding of 3H-labeled 
6-HD, displayed a slow but progressive loss of the 
capacity to accumulate norepinephrine, either in the 
presence or absence of 6HD, reaching a limit of 
approximately 45-50 percent after four hours. No 
loss in norepinephrine uptake was observed in 
control during this period. This slow but progressive 
decrease in the uptake capacity, which is independent 
of any further increase in the covalent binding of 
6HD, suggests that intraneuronal cross-linking of 
proteins may continue slowly foIlo~ng saturation 
of the binding sites for 6-HD. Direct attempts to 
characterize the formation of cross-linked proteins 
containing 3H-labeled 6-HD, utilizing the same 
tec~iques mentioned earlier in the neuroblastoma 
study, was not satisfactory, presumably because of 
the relatively insignificant quantities of neuronal 
protein present in atria. However, at least tive 
distinct proteins retaining isotope derived from 3H- 
labeled 6-HD could be demonstrated on disc-gel 
electrophoresis. Thus, it may be possible through 
immunoIo~ca1 tec~iques, util~ing ~tibodies 
specific for intraneuronal proteins, to isolate cross- 
linked protein polymers. While an absolute causal 
relationship between the covalent binding of the 
oxidation products of 6-HD to intracellular proteins 
and their subsequent cross-linking with the neuronal 
degeneration induced by 6-ND has yet to be established, 
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the present evidence strongly supports this view as 
the mechanism operative in vivo. 
In conclusion, it is suggested that one rational 
approach for the design of cell-specific toxic agents 
can be patterned on the example of 6-HD. The first 
requirement in this approach, upon which the 
necessary specificity of the agent is dependent, 
involves finding a system which selectively permits 
the accumulation of the agent in a cell-type. In the 
case of 6-HD, the accumulation is a consequence of 
the uptake mechanism in the sympathetic neuronal 
terminal for the natural substrate, norepinephrine. 
The search for systems in other cell-types involves 
a knowledge of the substrate specificity of transport 
mechanisms and the affinity or quantitative relation- 
ships of substrates for a transport system. The second 
requirement in this approach is the design of an 
agent which has an affinity for the cell type and can 
undergo some spontaneous or enzymatically catalyzed 
change to give rise to a product or products with 
at least two sites for reaction with nucleophilic sites 
on proteins. By analogy to the example of 6-HD, the 
toxicity must be a consequence of the accumulation 
of a relatively high, critical concentration within 
the specific cell-type. The general, nonspecific inter- 
actions with protein at concentration below this 
critical level are not cytotoxic. Thus the types of 
agents which fit this rationale are not necessarily 
extremely toxic or reactive compounds. 
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